REGENERON PHARMACEUTICALS INC. - COMMON STOCK

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

18 Jun 2024 10:33:40 By NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

17 Jun 2024 11:07:31 By NetDania Notify

Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma

16 Jun 2024 06:10:09 By Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

14 Jun 2024 09:47:23 By NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

13 Jun 2024 11:48:49 By NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

12 Jun 2024 09:57:35 By NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

11 Jun 2024 14:13:32 By NetDania Notify

Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)

11 Jun 2024 07:00:03 By Nasdaq GlobeNewswire

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

06 Jun 2024 10:10:34 By NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

05 Jun 2024 10:55:03 By NetDania Notify

NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

03 Jun 2024 10:29:14 By NetDania Notify

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD

31 May 2024 01:05:00 By Nasdaq GlobeNewswire

Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

31 May 2024 01:00:00 By Nasdaq GlobeNewswire

Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO

23 May 2024 17:03:17 By Nasdaq GlobeNewswire

Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine

20 May 2024 14:15:00 By Nasdaq GlobeNewswire

More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024

17 May 2024 13:45:49 By Nasdaq GlobeNewswire

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)

13 May 2024 01:00:00 By Nasdaq GlobeNewswire

Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks

08 May 2024 06:00:57 By Nasdaq GlobeNewswire

Regeneron Announces Investor Conference Presentations

06 May 2024 16:05:00 By Nasdaq GlobeNewswire

Regeneron Reports First Quarter 2024 Financial and Operating Results

02 May 2024 06:30:00 By Nasdaq GlobeNewswire